Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7515629 in HLA-G Positive Solid Tumors
NCT05769959Phase 1Terminated
- Sponsor
- Roche
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7515629 in solid tumor, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and 3 more (3 arms), sponsored by Roche. Primary endpoints: Adverse Events and Serious Adverse Events at 15 months and Dose Limiting Toxicities at 28 days. Started Jun 2023; status: terminated.
02
Drugs
RO7515629
03
Conditions
solid tumorrenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05769959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769959.